| scholarly article | Q13442814 |
| P2093 | author name string | Peuskens J | |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| patient | Q181600 | ||
| chronic schizophrenia | Q18967121 | ||
| risperidone | Q412443 | ||
| P304 | page(s) | 712-26; discussion 727-33 | |
| P577 | publication date | 1995-06-01 | |
| P1433 | published in | British Journal of Psychiatry | Q4035428 |
| P1476 | title | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group | |
| P478 | volume | 166 |
| Q41232979 | 5-HT2 antagonism and EPS benefits: is there a causal connection? |
| Q33606079 | A comparative review of new antipsychotics |
| Q43840719 | A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study |
| Q44452832 | A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia |
| Q46142676 | A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study |
| Q46545005 | A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia. |
| Q42628400 | A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group |
| Q36184129 | A pharmacoeconomics and formulary management collaborative project to teach decision analysis principles |
| Q51864823 | A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. |
| Q37058653 | A potential mechanism underlying atypical antipsychotics-induced lipid disturbances |
| Q47242918 | A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients |
| Q35035150 | A review of the effect of atypical antipsychotics on weight |
| Q35167958 | Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia |
| Q41060466 | Adverse effects of antipsychotic agents. Do newer agents offer advantages? |
| Q34583643 | Adverse effects of atypical antipsychotics : differential risk and clinical implications |
| Q60445497 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia |
| Q31114390 | An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms |
| Q36373454 | An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia |
| Q93144063 | Antipsychotic drugs: atypical advantages and typical disadvantages |
| Q43841264 | Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports |
| Q24236683 | Antipsychotic medication for early episode schizophrenia |
| Q34551484 | Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management |
| Q40527756 | Aripiprazole, a novel atypical antipsychotic drug |
| Q35665593 | Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care |
| Q40824970 | Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy |
| Q39412178 | Atypical antipsychotics: revolutionary or incremental advance? |
| Q34396636 | Atypical presentations of atypical antipsychotics. |
| Q71816815 | Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys |
| Q41733340 | Behavioural toxicity of medicinal drugs. Practical consequences, incidence, management and avoidance |
| Q51951486 | Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. |
| Q34340160 | Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications |
| Q32060406 | Bodyweight gain with atypical antipsychotics. A comparative review |
| Q33538059 | Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology |
| Q89145780 | Clinical Pharmacokinetics of Atypical Antipsychotics: An Update |
| Q36804367 | Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response |
| Q35728228 | Clinical pharmacology of atypical antipsychotics: an update. |
| Q36414518 | Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. |
| Q44202991 | Clozapine-induced weight gain predicts improvement in psychopathology |
| Q44042930 | Comment: risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine |
| Q44318884 | Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey |
| Q79840646 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia |
| Q33787546 | Conventional versus novel antipsychotics: changing concepts and clinical implications |
| Q35638077 | Cost comparisons of olanzapine and risperidone in treating schizophrenia |
| Q46896771 | Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. |
| Q77157460 | Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel |
| Q46442057 | Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. |
| Q79744901 | Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs |
| Q35073807 | Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences |
| Q34744036 | Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review |
| Q34544566 | Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms |
| Q73477695 | Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia |
| Q37598284 | Dose equivalents for second-generation antipsychotics: the minimum effective dose method |
| Q35820327 | Dose response and atypical antipsychotics in schizophrenia. |
| Q31399132 | Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina |
| Q34879022 | Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. |
| Q37227479 | Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features |
| Q40893820 | Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes |
| Q34455081 | Drug treatment of the negative symptoms of schizophrenia |
| Q40907387 | Drug treatments for schizophrenia - past, present and future |
| Q50538639 | Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. |
| Q35068139 | Economic evaluations of novel antipsychotic medications: a literature review |
| Q43846376 | Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements |
| Q73934511 | Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism |
| Q46808081 | Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. |
| Q34481227 | Effects of newer antipsychotics on extrapyramidal function |
| Q51994361 | Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah. |
| Q43334593 | Effects of specific dopamine D1 and D2 receptor antagonists and agonists and neuroleptic drugs on emotional defecation in a rat model of akathisia |
| Q34353074 | Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials |
| Q40824415 | Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials |
| Q33724292 | Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews |
| Q53988161 | Efficacy and safety of risperidone in psychotic patients: an open study. |
| Q35035133 | Efficacy of newer generation antipsychotics in the treatment of schizophrenia |
| Q90859591 | Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis |
| Q34560981 | Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia |
| Q31117818 | Estimating reliability and generalizability from hierarchical biomedical data |
| Q35623212 | Evidence-based treatment for schizophrenia |
| Q33256430 | Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report |
| Q34392465 | Extrapyramidal side effects are unacceptable |
| Q46486034 | Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. |
| Q28236854 | Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management |
| Q87917217 | Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study |
| Q41050424 | From evidence to conclusions in psychiatric research |
| Q40571172 | Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy |
| Q31161878 | Generalizability in nongaussian longitudinal clinical trial data based on generalized linear mixed models |
| Q48498123 | Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. |
| Q89458401 | How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials |
| Q55209638 | Impact of Drug Induced Long QT Syndrome: A Systematic Review. |
| Q35936881 | Impact of atypical antipsychotics on quality of life in patients with schizophrenia |
| Q83205849 | Influence of risperidone on balance control in young healthy individuals |
| Q46544794 | Interaction between escitalopram and risperidone. |
| Q41613931 | Introduction. Ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics |
| Q40623665 | Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology |
| Q33964357 | Is the PANSS used correctly? a systematic review. |
| Q79845789 | Linking the PANSS, BPRS, and CGI: clinical implications |
| Q46206792 | Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia |
| Q38377778 | Long-term skill proceduralization in schizophrenia |
| Q36433993 | Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis |
| Q35201017 | Management of the negative symptoms of schizophrenia: new treatment options |
| Q33604541 | Managing antipsychotic-induced parkinsonism |
| Q43664089 | Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach |
| Q60445500 | Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics |
| Q73625752 | Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group |
| Q28262051 | Neurological complications of psychiatric drugs: clinical features and management |
| Q41673381 | New antipsychotic medications: strategies for evaluation and selected findings |
| Q77482067 | New atypical antipsychotic medications |
| Q41475059 | New dimensions in the pharmacologic treatment of schizophrenia and related psychoses |
| Q30501297 | Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. |
| Q31440445 | Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group |
| Q35236514 | Optimizing dosing in atypical neuroleptic monotherapy |
| Q45238699 | Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study |
| Q35180801 | Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients |
| Q56880342 | Pharmaceutical company trials and the integrity of medical research |
| Q37609263 | Pharmacoeconomics of antipsychotic medications |
| Q40862596 | Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia |
| Q42603602 | Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers |
| Q34595112 | Pharmacological treatment of psychotic agitation |
| Q48776569 | Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group |
| Q34443837 | Placebo response in antipsychotic clinical trials: a meta-analysis |
| Q48391405 | Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients |
| Q44125238 | Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy |
| Q50896516 | Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. |
| Q48838612 | Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission? |
| Q44264675 | Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol |
| Q48496895 | Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia |
| Q84447459 | Quetiapine: Results of four phase II and III clinical trials |
| Q34392471 | Quetiapine: efficacy and tolerability in schizophrenia |
| Q38774660 | Recent antipsychotics in the treatment of psychoses |
| Q54135754 | Recent developments in the management of psychosis. |
| Q56880343 | Redundancy, disaggregation, and the integrity of medical research |
| Q45029914 | Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol |
| Q44626925 | Reversal of antipsychotic-induced weight gain during quetiapine treatment |
| Q51068243 | Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. |
| Q36982324 | Risperidone associated paralytic ileus in schizophrenia |
| Q35696059 | Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis |
| Q24240095 | Risperidone dose for schizophrenia |
| Q24242343 | Risperidone dose for schizophrenia |
| Q35612445 | Risperidone in acute and long-term therapy of schizophrenia--a clinical profile |
| Q50346452 | Risperidone in the treatment of childhood autistic disorder: an open pilot study. |
| Q34612481 | Risperidone in the treatment of psychoses in the elderly: a case report series |
| Q42550256 | Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials |
| Q57739451 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland |
| Q43722585 | Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response |
| Q43621469 | Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis |
| Q43512293 | Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial |
| Q42544120 | Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety |
| Q24241041 | Risperidone versus placebo for schizophrenia |
| Q55894951 | Risperidone versus placebo for schizophrenia |
| Q24248755 | Risperidone versus typical antipsychotic medication for schizophrenia |
| Q73101582 | Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies |
| Q42571132 | Risperidone-induced extrapyramidal reactions |
| Q33582654 | Risperidone. A pharmacoeconomic review of its use in schizophrenia |
| Q51991635 | Risperidone: treatment response in adult and geriatric patients. |
| Q77937406 | Schizophrenia: do we really need placebo-controlled studies? |
| Q35146132 | Schizophrenia: from phenomenology to neurobiology |
| Q38774790 | Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: a review |
| Q34530080 | Sexual dysfunction and antipsychotic treatment |
| Q46498342 | Sexual dysfunction in schizophrenics patients, the role of antipsychotics |
| Q84447463 | Sexual dysfunction: The unspoken side effect of antipsychotics |
| Q33890074 | Should the PANSS be rescaled? |
| Q35863003 | Simple Analysis Used in Diagnosis and Follow-up of Schizophrenic Patients (Patent). |
| Q42999954 | Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects |
| Q35073834 | State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics |
| Q44140145 | Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine |
| Q36276541 | Switching antipsychotics: an updated review with a focus on quetiapine |
| Q36626242 | Symptom domains of schizophrenia: the role of atypical antipsychotic agents |
| Q36346334 | Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia |
| Q33922103 | The Canadian experience with risperidone for the treatment of schizophrenia: an overview |
| Q31143463 | The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data |
| Q73963060 | The common marmoset (Callithrix jacchus) as a model for neuroleptic-induced acute dystonia |
| Q44202984 | The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia |
| Q33619940 | The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. |
| Q35102476 | The new and evolving pharmacotherapy of schizophrenia |
| Q33886331 | The newer, 'atypical' antipsychotic drugs--their development and current therapeutic use. |
| Q79359364 | The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients |
| Q35129876 | The relationships between depression and remission in first-episode psychosis |
| Q34367950 | The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial |
| Q33876248 | Tolerability of atypical antipsychotics |
| Q44506450 | Treatment for delirium with risperidone: results of a prospective open trial with 10 patients |
| Q51917811 | Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. |
| Q37006387 | Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. |
| Q30838181 | Using video-annotation software to identify interactions in group therapies for schizophrenia: assessing reliability and associations with outcomes. |
| Q43265630 | Weight gain associated with atypical antipsychotic drugs: mechanisms and management |
| Q34640811 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance |
| Q33223628 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia |
| Q79351323 | [Sexual behaviour in schizophrenic patients: the impact of antipsychotics] |
Search more.